Compare moats
Up to three covered companies, band by band. Every call is a curated editorial judgment, never a disclosed figure — and every band carries its cited basis.
| Eli Lilly and Company | Applied Digital | Applied Materials | |
|---|---|---|---|
| Moat rating | wide Eli Lilly's FY2025 10-K states "Intellectual property protection is critical" and that compound patents provide roughly 20-year market exclusivity ("patents in each relevant country last for a period of 20 years"), warning that loss of patent protection causes a "severe and rapid decline in revenues." Backed by an 83.0% gross margin (up from 81.3% in 2024) and a fast-growing, patent-protected incretin franchise (Mounjaro +99%, Zepbound +175% in 2025), the economic moat is wide and durable. Source: LLY FY2025 10-K. | none The FY2026 10-K (filed 2026-07-29) shows contracted revenue, not a demonstrated competitive edge. About 1,410 MW is leased under 15-year take-or-pay, non-cancellable base terms worth about $36.2 billion, but only about 100 MW of the roughly 1.5 GW that is contracted and either operating or under construction was operating and earning revenue at May 31, 2026, and Item 1A says "lessees may have the right to terminate applicable leases if there are significant delays in construction." Item 1A also concedes "We do not have the resources to compete with larger providers of similar products or services at this time," and the Competition section names 13 power-advantaged developers the company competes with. Signed leases give revenue visibility, but the filing does not show a durable advantage. | wide The FY2025 10-K (filed 2025-12-12) grounds a wide moat on three reinforcing pillars: (1) scale IP — 'more than 23,500 active patents in the United States and other countries' and $3.57B of fiscal 2025 RD&E spend that 'must generally enable us to deliver new products and technologies before the emergence of strong demand'; (2) portfolio breadth — 'the semiconductor capital equipment industry's most comprehensive portfolio of products', letting Applied 'combine, co-optimize and integrate our technologies to develop highly differentiated solutions'; (3) an installed-base annuity — the AGS segment monetizes 'our large, global installed base of semiconductor and other equipment' with transactional and subscription services, spares and factory automation software, carrying a $7,141M backlog (48% of the company's $15,002M total) at fiscal year-end 2025. Company gross margin expanded three straight years (46.7% FY2023, 47.5% FY2024, 48.7% FY2025) while this played out. |
| Moat type | intangibles ip Per the LLY FY2025 10-K, the pharma protection "anticipated to be of most relevance" is "patents claiming the active ingredient (the compound patent)," supplemented by regulatory data protection, FDA approvals, and brands — i.e., intangible assets. The 10-K notes that without such protection, products face intense generic and biosimilar price competition that erodes revenue quickly. | none The 10-K claims three advantages: power-advantaged sites (it believes securing power and interconnection ahead of demand is 'the principal constraint on new HPC capacity and a core differentiator for us from many of our competitors'), a standardized 'franchise-style' design, and hyperscaler master service and master telecom service agreements 'that are difficult to obtain.' The filing does not show any of them to be durable. Its Competition section says competition 'centers on securing and developing sites with access to large-scale, reliable, and cost-competitive power and interconnection' and names 13 power-advantaged developers going after the same leases, and Item 1A concedes it lacks the resources to compete with larger providers. Signed leases are take-or-pay and non-cancellable, so a tenant leaving for convenience owes 'the full remaining contractual value,' but that is contractual lock-in on each lease rather than a moat source, so no moat type is assigned. | intangibles ip The 10-K itself names IP as the competitive foundation: 'Protection of our technology assets through enforcement of our intellectual property rights, including patents, is important for our competitive position', backed by 'more than 23,500 active patents' plus trademarks, know-how, trade secrets and copyrights, and $3,570M of fiscal 2025 RD&E ($3,042M inside Semiconductor Systems alone). A strong secondary switching-cost layer is also documented: the risk factors cite the difficulty of 'securing development-tool-of-record (DTOR) and production-tool-of-record (PTOR) positions with customers' as a decisive competitive factor — once a tool is the record tool for a node, displacement is the exception — and AGS service/spares revenue is tied to the installed base. |
| Leadership | co leader Duopoly with Novo Nordisk: Novo's own FY2025 20-F names "Novo Nordisk and Eli Lilly [as] the most significant companies measured by market share" in the global diabetes and GLP-1 markets. Lilly is ascendant — the 20-F concedes Wegovy's years-long US anti-obesity prescription lead "was overtaken by a competing GLP-1 based product in the beginning of 2025" (Lilly's tirzepatide) — but Novo still cites Ozempic as "the leading product by sales," so co-leader is the honest band. Sources: Novo Nordisk FY2025 20-F; LLY FY2025 10-K. | behind The 10-K makes no leadership claim and gives no ranking or share figure. Item 1A concedes "We do not have the resources to compete with larger providers of similar products or services at this time" and that some rivals have "substantially greater liquidity and financial resources than we do." Its Competition section places APLD against established operators (Digital Realty, Equinix), hyperscalers that build their own capacity, independent developers and 13 named power-advantaged developers (IREN, Cipher Digital, TeraWulf, Hut 8, Riot, CleanSpark, HIVE, Core Scientific, Bitdeer, Galaxy Digital, Fermi, Keel Infrastructure, MARA). | clear leader Self-declared basis, not an independent rank: the 10-K's opening sentence claims Applied 'is the leader in the materials engineering solutions used to produce virtually every semiconductor in the world' and repeatedly claims 'the semiconductor capital equipment industry's most comprehensive portfolio'. The filing names no competitor and states no market-share figure — it acknowledges rivals ranging 'from small companies that compete in a single region... to global, diversified companies' and says only that 'many of our products have strong competitive positions'. Leadership claim is scoped to materials engineering (Applied sells no lithography). |
| Pricing power | moderate Mixed. The LLY 10-K shows an 83.0% gross margin (up 1.7pp), evidence of strong list-price power on exclusive branded drugs; but it repeatedly notes 2025 revenue growth was "partially offset by lower realized prices" for both Mounjaro and Zepbound, alongside heavy PBM/formulary rebate pressure and default anti-obesity coverage restrictions (e.g., US self-insured employers "must generally opt in" for obesity-drug coverage). Net pricing power is therefore moderate, not strong. | weak Item 1A says "Due to the limited number of hyperscalers, we expect that a limited number of customers will continue to account for a high percentage of our revenue for the foreseeable future," and that if customers' equipment usage declines or they discontinue use of its facilities, APLD "may be compelled to lower our lease prices in some instances or risk losing a significant customer." One customer was 59% of FY2026 revenue from continuing operations. Take-or-pay, non-cancellable terms protect contracted revenue over the base term, and Note 19 reports a $39.1M HPC Hosting segment profit on $385.3M of segment revenue in FY2026, but those terms are agreed with a small group of concentrated buyers. | strong MD&A attributes the FY2025 gross-margin expansion explicitly to price: margin rose 1.2 points to 48.7% 'primarily driven by higher net revenue, favorable changes in customer and product mix, an increase in average selling prices, and lower material and manufacturing costs' — the third consecutive annual increase (46.7% FY2023, 47.5% FY2024, 48.7% FY2025), with Semiconductor Systems segment gross margin at 54.2%. Counterweight from the same filing: a 'highly concentrated customer base' (two customers ~19% and ~15% of net revenue) whose members 'may seek pricing, payment, intellectual property-related, or other commercial terms that are less favorable to us'. |
| Summary | Lilly's moat rests on patent-protected, FDA-approved branded medicines led by its tirzepatide incretin franchise: per the FY2025 10-K, Mounjaro ($22.97B) and Zepbound ($13.54B) together generated roughly 56% of 2025's $65.2B revenue (up 99% and 175% respectively), while compound patents confer ~20-year market exclusivity and support an 83.0% gross margin. Durable competition only emerges after patents and regulatory data protection lapse, at which point the 10-K warns generics and biosimilars drive a "severe and rapid decline in revenues." | Applied Digital designs, builds and operates purpose-built, liquid-cooled HPC data centers, which it calls 'AI factories', and leases the capacity to CoreWeave and investment-grade hyperscalers. At May 31, 2026 its 10-K lists five campuses (Polaris Forge 1-3 and Delta Forge 1-2) with about 1,410 MW contracted under roughly 15-year take-or-pay, non-cancellable leases worth about $36.2 billion over the base terms. The filing claims three sources of advantage: it controls power-advantaged sites, it uses a standardized 'franchise-style' design built to deliver about 150 MW in about 14 to 18 months, and it holds hyperscaler master agreements that are 'difficult to obtain.' The same document shows how early the company is. About 100 MW was operating and earning revenue. One customer was 59% of FY2026 revenue from continuing operations. It competes with Digital Realty, Equinix, hyperscalers that build their own capacity and 13 named power-advantaged developers, and it concedes that it lacks the resources to compete with larger providers. Signed leases give long-dated revenue visibility, but the filing does not show a durable competitive advantage. | Applied Materials describes itself in its FY2025 10-K as 'the leader in the materials engineering solutions used to produce virtually every semiconductor in the world', selling wafer-fab equipment across patterning, transistor and interconnect fabrication (deposition/etch for 3D transistors), optical and eBeam process control, and advanced packaging. Fiscal 2025 net revenue was $28,368M: Semiconductor Systems $20,798M at a 54.2% gross margin (up from 52.9% FY2024 and 52.0% FY2023), AGS services $6,385M, and Corporate and Other (including display equipment) $1,185M. Within Semiconductor Systems, foundry/logic was 67% of revenue, DRAM 26%, NAND 7%. The moat mechanics the filing documents: 23,500+ active patents and $3.57B annual RD&E that must land tools with customers 'during early-stage technology selection'; DTOR/PTOR tool-of-record incumbency (cited in risk factors as the hard-to-win competitive position); and an AGS installed-base annuity whose backlog ($7,141M) now rivals the equipment backlog. The filing is equally clear about the moat's edges: 'Substantial competition exists across all the segments of our business'; two customers were approximately 19% and 15% of fiscal 2025 net revenue; ~89% of revenue is from outside the United States; and U.S. export controls on China 'have limited the market for certain of our products and services, adversely impacted our revenues and increased our exposure to foreign and Chinese domestic competition'. |
| Chain position | Upstream branded-drug originator. Per the FY2025 10-K, US distribution flows through three wholesalers (McKesson, Cencora, Cardinal Health), each accounting for over 10% of consolidated revenue, into consolidated PBMs/payers whose formularies and rebate demands constrain net price; Lilly is also expanding a direct-to-patient channel, LillyDirect. | Developer and landlord of power-advantaged, liquid-cooled AI data-center capacity, leased long-term to CoreWeave and investment-grade hyperscalers. | Upstream chokepoint of the AI-compute supply chain: Applied's tools fabricate chips for 'artificial intelligence (AI) and data center servers' among other end markets, selling into foundry/logic (67% of Semiconductor Systems revenue), DRAM (26%) and NAND (7%). Concentration cuts both ways — two customers were ~19% and ~15% of FY2025 net revenue, ~89% of revenue is non-U.S., and the customer base is 'geographically concentrated, particularly in China, Taiwan and Korea', with U.S. export controls on China constraining the addressable market and feeding Chinese domestic-equipment competition (all per the FY2025 10-K). |
| Products (share / barrier) |
|
|
|
| Long-horizon vote | +0.30 at weight 0.20 · swarm neutral Editorial prior, not backtested. | -0.20 at weight 0.20 · swarm neutral Editorial prior, not backtested. | +0.42 at weight 0.20 · swarm bullish Editorial prior, not backtested. |